Akroswiss
Akroswiss is a Swiss biotech company focused on developing innovative nasal treatments for CNS disorders, targeting unmet patient needs in epilepsy and anxiety-related conditions. They are developing a patented intranasal formulation with a unique 360° functionality, aiming for rapid, non-invasive, and hygienic drug delivery. The company is pursuing European marketing authorization for its midazolam product portfolio and is actively involved in R&D, clinical studies, and regulatory processes.
Industries
Nr. of Employees
small (1-50)
Products
Midazolam‑based intranasal spray for premedication (conscious sedation)
An intranasal, single‑use spray formulation intended to provide rapid, well‑tolerated premedication to reduce anxiety and claustrophobia during diagnostic or minor procedures.
Midazolam‑based intranasal rescue spray for epileptic seizures
An intranasal rescue formulation and bi‑dose delivery device intended for emergency treatment of epileptic seizures to provide rapid control and reduce progression to life‑threatening status.
Midazolam‑based intranasal spray for premedication (conscious sedation)
An intranasal, single‑use spray formulation intended to provide rapid, well‑tolerated premedication to reduce anxiety and claustrophobia during diagnostic or minor procedures.
Midazolam‑based intranasal rescue spray for epileptic seizures
An intranasal rescue formulation and bi‑dose delivery device intended for emergency treatment of epileptic seizures to provide rapid control and reduce progression to life‑threatening status.
Services
Product development and clinical study execution for intranasal CNS therapies
End‑to‑end development services including formulation development, device engineering, and clinical study execution to generate data for regulatory submissions.
Regulatory dossier compilation for EMA marketing authorization
Preparation and compilation of documentation required for submission to European regulatory authorities and initiation of applicable medical device regulatory processes.
Product development and clinical study execution for intranasal CNS therapies
End‑to‑end development services including formulation development, device engineering, and clinical study execution to generate data for regulatory submissions.
Regulatory dossier compilation for EMA marketing authorization
Preparation and compilation of documentation required for submission to European regulatory authorities and initiation of applicable medical device regulatory processes.
Expertise Areas
- Intranasal drug delivery
- Clinical trial management for CNS indications
- Medical device development and validation
- Regulatory submission preparation for EMA
Key Technologies
- Intranasal spray device engineering
- Bi‑dose nasal delivery mechanisms
- 360‑degree delivery design for nasal administration
- Nasal mucosal drug formulations